ML Research Intern - PhD (Winter/Summer 2025)

Genesis is building a world-class ML team in an industry that has underutilized computational methods for too long. We are creating the best molecular generation and property prediction platform in the world, filling in a critical piece in the drug discovery process. We need you to drive the cutting-edge research that will enable us to find cures for a wider range of diseases, faster than ever before.

You will

• Drive speed and accuracy improvements in our ML platform, coming up with architecture modifications for 2D and 3D graph neural networks, and rapidly implementing and testing them in pytorch
• Keep up with deep learning research, especially pertaining to graph neural nets and graph generative models, and quickly prototype ideas gleaned from the literature
• Dive deep into molecular datasets, creating statistically rigorous train, valid, and test sets to optimally train our models for real-world prediction and generation tasks
• Develop creative featurizations of 2D and 3D molecular structures that are inspired by laws of physics and chemistry, enabling our networks to take better advantage of available data
• Work closely with software engineers and medicinal chemists to make our ML platform maximally adaptive to different use cases
  
  
  
  
  

You are

• Currently enrolled in a PhD program in Computer Science, Machine Learning, or related fields
• Strong background in machine learning, deep learning, and/or related areas
• A deep thinker who reasons from first principles over pattern matching
• Interested in learning about biochemistry and the drug development process
  
  
  
  
  

What We Offer

• The opportunity to work on challenging, high impact ML research that is immediately deployed to accelerate the discovery of new medicines
• One-on-one mentorship to help guide your research and act as a point person for questions
• Strong technical coworkers in AI, software, and chemistry, who all have a powerful mix of intellectual curiosity and humility. The team reads and discusses 1-2 ML or chemistry papers every week to stay on top of the field and inspire new ideas
  
  
  
  
  

Genesis Therapeutics is unifying AI and biotech to discover novel and breakthrough treatments for patients with severe and devastating conditions. Genesis was founded on groundbreaking molecular ML research and since has established itself as the industry leader in AI for small molecule drug discovery. Our team of accomplished biotech leaders and expert drug hunters joins forces with deep learning researchers and software engineers who are pioneering predictive and generative AI technologies for molecules.

Our team has created the industry's most advanced molecular AI platform called GEMS (Genesis Exploration of Molecular Space), to accelerate and optimize small molecule drug discovery and to enable the discovery of novel first-in-class and best-in-class small molecule drugs for challenging and/or undruggable targets.

The company has leveraged GEMS to build an internal pipeline with multiple programs against high-value targets, including data-poor and canonically undruggable targets where GEMS is uniquely advantaged. In addition, Genesis has three AI platform collaborations across a range of therapeutic areas, with Gilead Sciences, Eli Lilly, and Genentech.

We raised a $200M series B in August 2023, and have raised over $300M in funding from top technology and biotech investors, including Andreessen Horowitz, Rock Springs Capital, T. Rowe Price, Fidelity, Radical Ventures, NVentures (NVIDIA's VC arm), BlackRock, and Menlo Ventures.

Genesis is headquartered in Burlingame, CA, with a fully integrated laboratory in San Diego. We are proud to be an inclusive workplace and an Equal Opportunity Employer.